SPHK1 and melanoma: Finally, SphK1 inhibition by the sphingosine-competitive inhibitor PF-543 [116] or Sphk1 downregulation by shRNA [89] enhanced the efficacy of immune checkpoint blockade therapies in murine melanoma models, reducing Treg induction and infiltration, respectively.